Zurcher Kantonalbank (Zurich Cantonalbank) C4 Therapeutics, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 08, 2023	BUY	$3.1 - $9.02 $7,998 - $23,271	2,580 Added 75.42%	6,001 $18,000
Q4 2021 Feb 01, 2022	BUY	$29.39 - $46.86 $100,543 - $160,308	3,421 New	3,421 $110,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

Lynx1 Capital Management LP San Juan, PR

6.88M
Shares

$30.1 Million
14.04% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

6.6M
Shares

$28.9 Million
3.2% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

5.68M
Shares

$24.9 Million
0.16% of portfolio
Ra Capital Management, L.P. Boston, MA

4.88M
Shares

$21.4 Million
0.39% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$19.9 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $214M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account